New suction device aims to quickly clear lung clots in emergency setting
NCT ID NCT07685522
First seen Jul 06, 2026 · Last updated Aug 26, 2026 · Updated 3 times
Summary
This study tests a new device called the Vibrato Aspiration System, designed to remove blood clots from the lungs in people with acute pulmonary embolism (a sudden blockage in the lung artery). The trial includes up to 10 adults aged 18 to 75 who have had symptoms for 14 days or less and meet specific criteria. The goal is to see if the device is safe and can reduce the strain on the heart caused by the clot.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vibrato Aspiration System (mechanical thrombectomy device)
- What this could lead to
- If successful, this device could offer a less invasive way to quickly remove dangerous blood clots from the lungs, potentially reducing complications and improving recovery.
- What could go wrong
- This is a very early, small study (first in humans) with only 10 participants. The device may cause bleeding, vessel injury, or other serious side effects, and its effectiveness is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects must meet all following general inclusion criteria: 1. Age ≥ 18 and ≤ 75 years. 2. Clinical signs, symptoms, and presentation consistent with acute PE; 3. PE symptom duration ≤ 14 days; 4. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery) 5. RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined). 6. Systolic blood pressure ≥ 90 mmHg; 7. Stable heart rate \< 130 BPM prior to procedure; 8. Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment 9. Informed Consent Form signed 10. Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit Exclusion Criteria: Subjects must not meet any of the following general exclusion criteria: 1. Thrombolytic use within 30 days of baseline CT angiogram 2. Pulmonary hypertension with peak pulmonary artery pressure \> 70 mmHg by right heart catheterization (site determined) 3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg; 4. FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%; 5. Hematocrit \< 28%; 6. Platelets \< 100,000/ML; 7. Serum creatinine \> 1.8 mg/dL; 8. International normalized ratio (INR) \> 3; 9. Major trauma injury severity score (ISS) \> 15 within the past 14 days 10. Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators; 11. Cardiovascular or pulmonary surgery within last 7 days; 12. Actively progressing cancer requiring chemotherapy 13. Known bleeding diathesis or coagulation disorder; 14. Left bundle branch block; 15. History of severe or chronic pulmonary arterial hypertension; 16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%; 17. History of uncompensated heart failure; 18. History of underlying lung disease that is oxygen dependent; 19. History of chest irradiation; 20. History of heparin-induced thrombocytopenia (HIT); 21. Patients who are under intubation 22. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants; 23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated; 24. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention; 25. Life expectancy of \< 90 days, as determined by Investigator; 26. Female who is pregnant or nursing; 27. Current participation in another investigational drug or device treatment study 28. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days 29. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary embolism acute are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
RECRUITINGKrakow, Lesser Poland Voivodeship, 31-202, Poland
-
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
NOT_YET_RECRUITINGPoznan, Greater Poland Voivodeship, 61-848, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Clot-Removing device ease acute pulmonary embolism?
- Can a catheter device clear lung clots and ease heart strain?
- Which blood thinner is safer for lung clots? a Head-to-Head test
- Can a simple electrical scan spot dangerous lung clots without radiation?
- Blood test may spot hidden heart danger in lung clots
- Heart patients get flu shot at discharge to prevent future attacks